Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. NVDA
2. PCG
3. AMZN
4. AAPL
5. AVGO
6. STLA
7. ALNY
8. CNS
9. BRVE
10. SPY

Go back to Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
(NASDAQ: RAIN) Delayed: 0.91 -0.08 (8.08%)
Previous Close $0.99    52 Week High $ 
Open $0.97    52 Week Low $ 
Day High $0.97    P/E N/A 
Day Low $0.90    EPS $ 
Volume 38,992